{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:16:39Z","timestamp":1791206199854,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"General Research Fund of Hong Kong"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81871499"],"award-info":[{"award-number":["81871499"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Nanotechnol."],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41565-024-01800-4","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T07:04:59Z","timestamp":1730099099000},"page":"167-176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Filamentous phages as tumour-targeting immunotherapeutic bionanofibres"],"prefix":"10.1038","volume":"20","author":[{"given":"Hui","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9637-2308","authenticated-orcid":false,"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yecheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1256-6514","authenticated-orcid":false,"given":"Mingying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8142-3659","authenticated-orcid":false,"given":"Chuanbin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"1800_CR1","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1126\/science.1185837","volume":"328","author":"JD Shields","year":"2010","unstructured":"Shields, J. D., Kourtis, I. C., Tomei, A. A., Roberts, J. M. & Swartz, M. A. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328, 749\u2013752 (2010).","journal-title":"Science"},{"key":"1800_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","volume":"18","author":"B Sangro","year":"2021","unstructured":"Sangro, B., Sarobe, P., Hervas-Stubbs, S. & Melero, I. Advances in immunotherapy for hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 18, 525\u2013543 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1800_CR3","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","volume":"12","author":"RK Vaddepally","year":"2020","unstructured":"Vaddepally, R. K., Kharel, P., Pandey, R., Garje, R. & Chandra, A. B. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers 12, 738 (2020).","journal-title":"Cancers"},{"key":"1800_CR4","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455\u20132465 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1800_CR5","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1093\/annonc\/mdy232","volume":"29","author":"AR Hansen","year":"2018","unstructured":"Hansen, A. R. et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann. Oncol. 29, 1807\u20131813 (2018).","journal-title":"Ann. Oncol."},{"key":"1800_CR6","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","volume":"23","author":"C Antoniotti","year":"2022","unstructured":"Antoniotti, C. et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 23, 876\u2013887 (2022).","journal-title":"Lancet Oncol."},{"key":"1800_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255\u2013265 (2017).","journal-title":"Lancet"},{"key":"1800_CR8","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/s41591-019-0474-7","volume":"25","author":"RJ Sullivan","year":"2019","unstructured":"Sullivan, R. J. et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat. Med. 25, 929\u2013935 (2019).","journal-title":"Nat. Med."},{"key":"1800_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11060-018-2955-9","volume":"140","author":"RV Lukas","year":"2018","unstructured":"Lukas, R. V. et al. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J. Neurooncol. 140, 317\u2013328 (2018).","journal-title":"J. Neurooncol."},{"key":"1800_CR10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab, H. O. et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front. Pharm. 8, 561 (2017).","journal-title":"Front. Pharm."},{"key":"1800_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1800_CR12","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1800_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40425-018-0459-y","volume":"7","author":"U Keilholz","year":"2019","unstructured":"Keilholz, U. et al. Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. J. Immunother. Cancer 7, 12 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1800_CR14","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","volume":"34","author":"C Massard","year":"2016","unstructured":"Massard, C. et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin. Oncol. 34, 3119\u20133125 (2016).","journal-title":"J. Clin. Oncol."},{"key":"1800_CR15","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang, D. Y. et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 4, 1721\u20131728 (2018).","journal-title":"JAMA Oncol."},{"key":"1800_CR16","doi-asserted-by":"publisher","first-page":"10400","DOI":"10.1073\/pnas.1601060113","volume":"113","author":"P Manrique","year":"2016","unstructured":"Manrique, P. et al. Healthy human gut phageome. Proc. Natl Acad. Sci. USA 113, 10400\u201310405 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1800_CR17","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","volume":"25","author":"RM Dedrick","year":"2019","unstructured":"Dedrick, R. M. et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat. Med. 25, 730\u2013733 (2019).","journal-title":"Nat. Med."},{"key":"1800_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1473-3099(18)30482-1","volume":"19","author":"P Jault","year":"2019","unstructured":"Jault, P. et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1\/2 trial. Lancet Infect. Dis. 19, 35\u201345 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"1800_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33294-w","volume":"13","author":"B Van Nieuwenhuyse","year":"2022","unstructured":"Van Nieuwenhuyse, B. et al. Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler. Nat. Commun. 13, 5725 (2022).","journal-title":"Nat. Commun."},{"key":"1800_CR20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41564-019-0634-z","volume":"5","author":"A Petrovic Fabijan","year":"2020","unstructured":"Petrovic Fabijan, A. et al. Safety of bacteriophage therapy in severe Staphylococcus aureus infection. Nat. Microbiol 5, 465\u2013472 (2020).","journal-title":"Nat. Microbiol"},{"key":"1800_CR21","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s40425-019-0705-y","volume":"7","author":"H Liu","year":"2019","unstructured":"Liu, H. et al. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy. J. Immunother. Cancer 7, 270 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1800_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.119984","volume":"247","author":"S Gurung","year":"2020","unstructured":"Gurung, S. et al. Phage display-identified PD-L1-binding peptides reinvigorate T-cell activity and inhibit tumor progression. Biomaterials 247, 119984 (2020).","journal-title":"Biomaterials"},{"key":"1800_CR23","doi-asserted-by":"publisher","first-page":"11760","DOI":"10.1002\/anie.201506225","volume":"54","author":"HN Chang","year":"2015","unstructured":"Chang, H. N. et al. Blocking of the PD-1\/PD-L1 interaction by a D-peptide antagonist for cancer immunotherapy. Angew. Chem. Int. Ed. Engl. 54, 11760\u201311764 (2015).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"1800_CR24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1158\/2326-6066.CIR-17-0035","volume":"6","author":"C Li","year":"2018","unstructured":"Li, C. et al. Peptide blocking of PD-1\/PD-L1 interaction for cancer immunotherapy. Cancer Immunol. Res. 6, 178\u2013188 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"1800_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202001260","volume":"32","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Selectively suppressing tumor angiogenesis for targeted breast cancer therapy by genetically engineered phage.Adv. Mater. 32, e2001260 (2020).","journal-title":"Adv. Mater."},{"key":"1800_CR26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3109\/08923973.2015.1027917","volume":"37","author":"M Asadi-Ghalehni","year":"2015","unstructured":"Asadi-Ghalehni, M. et al. Cancer immunotherapy by a recombinant phage vaccine displaying EGFR mimotope: an in vivo study. Immunopharmacol. Immunotoxicol. 37, 274\u2013279 (2015).","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"1800_CR27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s43018-020-0075-x","volume":"1","author":"SA Oh","year":"2020","unstructured":"Oh, S. A. et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat. Cancer 1, 681\u2013691 (2020).","journal-title":"Nat. Cancer"},{"key":"1800_CR28","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1002\/pmic.200300680","volume":"4","author":"S Mandava","year":"2004","unstructured":"Mandava, S., Makowski, L., Devarapalli, S., Uzubell, J. & Rodi, D. J. RELIC\u2014a bioinformatics server for combinatorial peptide analysis and identification of protein\u2013ligand interaction sites. Proteomics 4, 1439\u20131460 (2004).","journal-title":"Proteomics"},{"key":"1800_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/srep14802","volume":"5","author":"K Hodyra-Stefaniak","year":"2015","unstructured":"Hodyra-Stefaniak, K. et al. Mammalian host-versus-phage immune response determines phage fate in vivo. Sci. Rep. 5, 14802 (2015).","journal-title":"Sci. Rep."}],"container-title":["Nature Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41565-024-01800-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41565-024-01800-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41565-024-01800-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T17:35:34Z","timestamp":1737480934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41565-024-01800-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1800"],"URL":"https:\/\/doi.org\/10.1038\/s41565-024-01800-4","relation":{},"ISSN":["1748-3387","1748-3395"],"issn-type":[{"value":"1748-3387","type":"print"},{"value":"1748-3395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"25 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}